Nobiletin

Nobiletin is a polymethoxylated flavonoid concentrated in citrus peels, particularly sweet oranges and tangerines, that exerts anti-inflammatory and metabolic effects primarily by inhibiting NF-κB signaling and modulating AMPK activation. Research in animal models suggests it may support cardiovascular health, glucose metabolism, and neuroprotection, though robust human clinical trials remain limited.

Origin & History

Nobiletin is a polymethoxylated flavonoid naturally found in citrus fruits, particularly concentrated in the peel and white pith of sweet oranges (Citrus sinensis), mandarins, and tangerines. It is extracted through solvent extraction methods, with standardized extracts typically containing 95% or greater pure nobiletin.

Historical & Cultural Context

Nobiletin has minimal traditional use as it was only isolated and characterized in the late 20th century. While citrus peel (Chen Pi) has been used in Traditional Chinese Medicine for digestive complaints, nobiletin itself is a modern phytochemical discovery with use based entirely on contemporary research rather than historical practice.

Health Benefits

• May support cardiovascular health by reducing oxidative stress and improving vascular function (preliminary evidence from diabetic rat models, PMID: 27279123)
• May help maintain healthy platelet function and blood flow (in vitro and mouse studies show platelet aggregation inhibition, PMID: PMC4543618)
• May support brain health by reducing neuroinflammation (cell culture studies demonstrate microglial protection, PMID: 41261295)
• May help reduce amyloid plaque formation associated with Alzheimer's disease (APP transgenic mouse studies, PMID: 18544674)
• May provide anti-inflammatory support through selective COX-2 inhibition (in vitro studies, PMID: 12787887)

How It Works

Nobiletin suppresses inflammatory gene expression by inhibiting the NF-κB signaling cascade, reducing downstream production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. It activates AMP-activated protein kinase (AMPK), which improves insulin sensitivity and lipid metabolism by upregulating fatty acid oxidation and inhibiting lipogenic enzyme expression. Additionally, nobiletin inhibits phosphodiesterase (PDE) enzymes, elevating intracellular cAMP and cGMP levels, which contributes to its vasodilatory and platelet aggregation-inhibiting effects.

Scientific Research

Important: No human clinical trials have been published for nobiletin. All available evidence comes from preclinical studies including diabetic rat models (PMID: 27279123), platelet function studies in mice (PMID: PMC4543618), and neuroinflammation cell culture models (PMID: 41261295).

Clinical Summary

The majority of nobiletin research consists of in vitro cell studies and rodent models, with very few controlled human trials published to date. In diabetic rat models, nobiletin administration reduced oxidative stress markers and improved endothelial vascular function (PMID: 27279123), while mouse studies demonstrated significant inhibition of collagen- and ADP-induced platelet aggregation. A small number of human observational studies link high dietary polymethoxylated flavonoid intake to improved lipid profiles, but these do not isolate nobiletin specifically. Overall, the evidence base is preliminary and promising but insufficient to establish definitive clinical recommendations for humans.

Nutritional Profile

Nobiletin is a polymethoxylated flavone (PMF) isolated primarily from citrus peel, particularly sweet orange (Citrus sinensis) and tangerine (Citrus reticulata). It is not a macronutrient or micronutrient source but rather a bioactive polyphenolic compound with molecular formula C21H22O8 and molecular weight 402.39 g/mol. Typical concentrations in citrus peel range from 0.1–1.5 mg/g dry weight, with tangeretin and sinensetin often co-occurring as related PMFs. As a pure compound, it contains no meaningful protein, fiber, or mineral content. Bioavailability is limited by poor aqueous solubility (log P ~3.6), though its methoxy groups confer significantly better intestinal absorption compared to non-methylated flavones like luteolin. Gut microbiota partially demethylate nobiletin into active metabolites (e.g., 3',4'-dihydroxynobiletin), which may contribute to downstream bioactivity. Peak plasma concentrations in rodent studies are typically achieved 1–2 hours post-oral administration, with lipid-based delivery systems shown to enhance bioavailability by approximately 2–3 fold.

Preparation & Dosage

No established human dosing exists as no clinical trials have been conducted. Animal studies used 10-25 mg/kg orally in rats and 50 μM in mice. Commercial citrus extracts typically provide 50-500 mg per serving standardized to 10-30% nobiletin content. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Nobiletin pairs well with Quercetin, as both inhibit NF-κB and MAPK inflammatory pathways through complementary mechanisms — nobiletin suppresses COX-2 expression while quercetin inhibits lipoxygenase activity, producing additive anti-inflammatory effects. Combining nobiletin with Omega-3 fatty acids (EPA/DHA) is strategically beneficial because the lipid matrix enhances nobiletin's intestinal absorption while EPA/DHA contribute independent anti-inflammatory and cardiovascular benefits via eicosanoid pathway modulation, reducing platelet aggregation through overlapping but distinct targets (TXA2 suppression by EPA vs. cAMP elevation by nobiletin). Piperine (from black pepper, at ~5–20 mg doses) can inhibit CYP3A4-mediated hepatic metabolism of nobiletin, extending its plasma half-life and systemic exposure, similar to its well-documented enhancement of curcumin bioavailability; additionally, pairing nobiletin with Resveratrol may produce complementary neuroprotective synergy, as both activate AMPK and SIRT1 pathways while nobiletin additionally inhibits PDE4-mediated cAMP degradation, potentially amplifying neuronal signaling benefits observed in preclinical models.

Safety & Interactions

Nobiletin is generally considered well-tolerated in animal studies at dietary-relevant doses, with no significant toxicity reported at moderate supplemental levels, but comprehensive human safety data are lacking. Because nobiletin inhibits certain cytochrome P450 enzymes, including CYP3A4 and CYP1A2, it may theoretically alter the metabolism of drugs such as statins, calcium channel blockers, and anticoagulants like warfarin, potentially increasing their plasma concentrations. Its platelet aggregation-inhibiting properties suggest caution when combined with antiplatelet drugs such as aspirin or clopidogrel, or anticoagulants, due to additive bleeding risk. Pregnant or breastfeeding individuals should avoid supplemental nobiletin due to the absence of safety data in these populations.